Here, a modified αCGRP analogue with an albumin binding fatty acid moiety showed protracted pharmacokinetic properties (Nilsson et al., 2016; Sheykhzade et al., 2018) and demonstrated positive utility in alleviating or reversing cardiovascular disease in rodents (Aubdool et al., 2017). The gene discussed is ALB; the disease is cardiovascular disorder.